The historical rank and industry rank for Bicycle Therapeutics's FCF Margin % or its related term are showing as below:
STU:50BA'
s FCF Margin % Range Over the Past 10 Years
Min: -726.67 Med: -235.61 Max: -122.72
Current: -367.56
During the past 9 years, the highest FCF Margin % of Bicycle Therapeutics was -122.72%. The lowest was -726.67%. And the median was -235.61%.
STU:50BA's FCF Margin % is ranked worse than 67.6% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs STU:50BA: -367.56
Bicycle Therapeutics FCF Margin % Related Terms
Bicycle Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bicycle Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:50BA vs ABEO, DMAC, FATE: FCF Margin % Comparison
For the Biotechnology subindustry, Bicycle Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicycle Therapeutics (STU:50BA) has a FCF Margin % of -7,515.25% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bicycle Therapeutics and its competitors. According to the industry distribution chart, Bicycle Therapeutics ranks #649 out of 960 companies in the Biotechnology industry, placing it in the top 67.6%.
Is Bicycle Therapeutics' FCF Margin % too high?
Bicycle Therapeutics' current FCF Margin % is -7,515.25%. Based on the distribution chart, Bicycle Therapeutics ranks #649 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bicycle Therapeutics has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' FCF Margin % compare to ABEO and DMAC?
According to the Biotechnology industry distribution chart, Bicycle Therapeutics ranks #649 out of 960 companies for FCF Margin %. This places Bicycle Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bicycle Therapeutics and its competitors. Bicycle Therapeutics's current FCF Margin % is -7,515.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (STU:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €12.91, compared to a current price of €3.46 — trading 73.2% below its estimated fair value. The current FCF Margin % is -7,515.25%. Bicycle Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bicycle Therapeutics (STU:50BA), the current FCF Margin % is -7,515.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bicycle Therapeutics (STU:50BA) Overvalued in 2026?
Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued.
The current stock price of €3.46 is trading 73.2% below its estimated GF Value™ of €12.91.
GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.
Key valuation signals for STU:50BA:
FCF Margin %: -7,515.25%
GF Value™: €12.91 vs. price of €3.46 (73.2% below fair value)
No single metric tells the full story. See the STU:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
54GF Score
Get the complete analysis for STU:50BA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:50BA has been successfully added to your 
